KRONOX

Date: November 05, 2026

To, **National Stock Exchange of India Limited** Exchange Plaza, C-1 Block G, Bandra Kurla Complex Bandra [E], Mumbai – 400051 NSE Scrip Symbol: **KRONOX**	To, **BSE Limited** 25th Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 BSE Scrip Code: **544187**

Subject: Submission of Statement of Standalone Unaudited Financial Results for the quarter and half year ended on September 30, 2026 along with the Statement of Assets and Liabilities as on September 30, 2026.

Dear Sir/Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that, Board of Directors at their meeting held today i.e. on **Thursday, November 05, 2026,** have considered, approved and took on record the followings:

1. Statement of Standalone Unaudited Financial Results for the quarter and half year ended on September 30, 2026 along with Statement of Assets and Liabilities as at September 30, 2026 and the Cash Flow Statement for the quarter and half-year ended on September 30, 2026

2. Independent Auditors' Limited Review Report on Financial Results.

The Meeting of Board of Directors commenced at 12:15 p.m. and concluded at 2:00 p.m.

Kindly take the aforesaid information on your record and oblige.

Thanking you

For **KRONOX Lab Sciences Limited**

KRONOX LAB SCIENCES LTD. VADODARA

Nikhil Goswami
Company Secretary & Compliance Officer
Membership No. A68272

KRONOX

KRONOX LAB SCIENCES LIMITED

Regd. Office: Block No. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 Gujarat

email: cs@kronoxlabsciences.com ; CIN: L24117GJ2008PLC055460

Statement of Unaudited Financial Results for the Quarter and Six Months ended September 30, 2026

(Rs in lakhs)

Sr. No.	Particulars	Quarter ended			Six Months ended		Year ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**INCOME FROM OPERATIONS**						
	Revenue from Operations	2,683.42	2,838.64	2,553.32	5,522.06	4,981.97	10,122.00
	Other Income	86.87	129.66	104.21	216.53	191.53	519.40
	TOTAL INCOME	**2,770.29**	**2,968.30**	**2,657.53**	**5,738.59**	**5,173.50**	**10,641.40**
2	**EXPENSES**						
	a. Cost of Materials Consumed	1,108.38	1,509.30	1,021.42	2,617.68	2,308.65	4,713.80
	b. Changes in Inventories of Finished Goods, Work in Progress and Stock-In-Trade	112.01	(111.40)	114.97	0.61	(8.11)	(56.20)
	c. Employee Benefit Expenses	190.60	193.30	184.01	383.90	362.41	740.30
	d. Finance Costs	7.85	3.30	3.92	11.15	3.92	11.40
	e. Depreciation and Amortisation Expenses	49.45	45.20	46.84	94.65	86.90	204.80
	f. Other Expenses	428.64	347.60	368.37	776.24	646.29	1,297.00
	TOTAL EXPENSES	**1,896.93**	**1,987.30**	**1,739.53**	**3,884.23**	**3,400.06**	**6,911.10**
3	**Profit/loss from operations before Tax (1-2)**	**873.36**	**981.00**	**918.00**	**1,854.36**	**1,773.44**	**3,730.30**
4	**Tax Expenses**						
	a. Current Tax	233.97	253.00	250.00	486.97	468.60	972.00
	b. Deferred Tax	(4.64)	(2.30)	0.37	(6.94)	(2.05)	(7.70)
	Total Tax Expenses	**229.33**	**250.70**	**250.37**	**480.03**	**466.55**	**964.30**
5	**Profit after Tax for the Period (3-4)**	**644.03**	**730.30**	**667.63**	**1,374.33**	**1,306.89**	**2,766.00**
6	**Other Comprehensive Income**						
	Item that will not be reclassified to profit or loss						
	i. Defined benefit Plan liability/assets	0.59	(4.00)	7.94	(3.41)	11.19	29.00
	ii. Tax Impact on above item	(0.14)	1.00	(2.00)	0.86	(2.82)	(7.30)
		0.45	**(3.00)**	**5.94**	**(2.55)**	**8.37**	**21.70**
7	**Total Comprehensive Income for the Period (5+6)**	**644.48**	**727.30**	**673.57**	**1,371.78**	**1,315.26**	**2,787.70**
8	Paid-up Equity Share Capital (FV Rs.10/- per share)	3,710.40	3,710.40	3,710.40	3,710.40	3,710.40	3,710.40
9	Reserves excluding Revaluation reserve						7,902.29
10	Earning Per Equity Share (in Rs)						
	Basic and Diluted	1.73	1.97	1.80	3.70	3.52	7.45

Notes:

1 The above results have been reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their respective Meeting held on November 05, 2026.

2 The Company is having only one segment of activity namely 'Manufacturing and Selling of of High Purity Speciality Fine Chemical' the disclosure requirement of the Indian Accounting Standard (AS) 108 "Operating Segments" notified under Section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rule, 2014 are not applicable.

3 The Statutory Auditors have carried out a Limited Review of the unaudited Financial Results and have expressed an unmodified review report.

KRONOX LAB SCIENCES LTD. VADODARA

4 Pursuant to Share Purchase Agreement executed between the erstwhile Promoters of the Company and Indo Borax & Chemicals Limited on August 20, 2026, the Equity Shares of the Company representing 64.26% of the Paid-up Equity Shares Capital were transferred to Indo Borax & Chemicals Limited on September 29, 2026. Consequently, Indo Borax Chemicals Limited became the Holding Company. Pursuant to change in controlling stake in the Company, there is a change in the Board of Directors and Key Managerial Personnel of the Company effective from September 29, 2026.

5 Previous period figures have been regrouped/reclassified , wherever necessary, to make them comparable with the figures for the current period.

For and on behalf of the Board of Directors

KRONOX LAB SCIENCES LTD. VADODARA

Mr. Suresh Kalra
Managing Director & CEO
DIN: 02833715

Place: Mumbai
Date : November 05, 2026

KRONOX LAB SCIENCES LIMITED
CIN: L24117GJ2008PLC055460

Statement of Assets and Liabilities as on September 30, 2026

(Rs in lakhs)

Particulars	As at 30.09.2026 (Unaudited)	As at 31.03.2026 (Audited)
Assets		
I. Non-Current Assets		
(a) Property, Plant and Equipment	2,868.03	2,873.34
(b) Capital Work-in-Progress	180.80	87.56
(c) Financial Assets		
(i) Investments	2.50	2.50
(ii) Other Financial Asset	10.32	1,864.25
(d) Deferred Tax Asset (net)	48.04	40.24
	3,109.69	4,867.89
II. Current Assets		
(a) Inventories	740.13	836.95
(b) Financial assets		
(i) Trade Receivables	1,882.13	2,118.52
(ii) Cash and Cash Equivalent	944.49	274.62
(iii) Bank balances other than (ii) above	7,007.56	4,599.47
(c) Other Current Assets	125.55	54.81
	10,699.86	7,884.37
Total Assets	**13,809.55**	**12,752.26**
Equity and liabilities		
Equity		
(a) Equity Share Capital	3,710.40	3,710.40
(b) Other Equity	9,088.24	7,902.29
Total Equity	**12,798.64**	**11,612.69**
Liabilities		
I. Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	100.42
(b) Provisions	15.46	2.37
	15.46	102.79
II. Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	-	60.27
(ii) Trade Payables		
Total outstanding dues of Micro Enterprise and Small Enterprise	295.55	189.64
Total outstanding dues of Creditors other than Micro Enterprise and Small Enterprise	537.68	468.48
(iii) Other Financial Liabilities	0.54	0.16
(b) Other Current Liabilities	40.54	123.97
(c) Provisions	44.58	53.22
(d) Current Tax Liabilities (Net)	76.56	141.04
	995.45	1,036.78
Total Equity and Liabilities	**13,809.55**	**12,752.26**

KRONOX LAB SCIENCES LTD. VADODARA

KRONOX LAB SCIENCES LIMITED
CIN: L24117GJ2008PLC055460

KRONOX

Unaudited Statement of Cash Flow for the Six Months ended September 30, 2026

(Rs in lakhs)

Particulars		6 months ended 30.09.2026	6 months ended 30.09.2025
A CASH FLOW FROM OPERATING ACTIVITIES			
Net profit before tax		**1,854.36**	**1,773.44**
Adjustments for:			
Depreciation and amortisation		94.65	86.90
Profit On Sale of Property, Plant & Equipment		-	-
Finance Cost		11.15	-
Interest Income		(160.03)	(121.24)
Accrued Defined Benefit Plan Liability		9.92	13.93
Cash generated from Operations Profit before Working Capital Changes		**1,810.05**	**1,753.03**
Adjustments for:			
Trade Receivables		236.39	(63.90)
Other Current Assets		(70.72)	(42.35)
Inventories		96.83	(119.69)
Trade payables & Provisions		166.19	35.94
Other Current and Non Current Liabilities		(147.64)	(44.70)
		281.05	**(234.70)**
Cash Generated from Operations		**2,091.10**	**1,518.33**
Direct Taxes paid		(486.97)	(468.60)
Net Cash generated from operating activities	(i)	**1,604.13**	**1,049.73**
B CASH FLOW FROM INVESTING ACTIVITIES			
Payment for Purchase of Property, Plant and Eqiupment and Capital Work in Progress		(182.60)	(303.05)
Bank Deposits (Placed)/Matured		(554.16)	(1,009.05)
Proceeds from Sale of Property,Plant & Equipment		-	26.56
Interest received		160.03	121.24
Net cash generated from investing activities	(ii)	**(576.73)**	**(1,164.30)**
C CASH FLOW FROM FINANCING ACTIVITIES			
Interest Paid		(11.15)	-
Payment of Dividends		(185.69)	(185.34)
Proceeds/(Repayments) of borrowings		(160.69)	261.40
Net cash generated from financing activities	(iii)	**(357.53)**	**76.06**
Net change in cash and cash equivalents	(i+ii+iii)	**669.87**	**(38.51)**
Cash and cash equivalents at the beginning of the year		274.62	303.55
Cash and cash equivalents at the end of the period*		**944.49**	**265.04**
***Cash and Cash equivalents includes:**			
Cash in hand		0.44	1.70
Balances with Scheduled Bank & Fixed Depsoits		944.05	263.34
		944.49	**265.04**

KRONOX LAB SCIENCES LTD. VADODARA

MAHESH UDHWANI & ASSOCIATES
CHARTERED ACCOUNTANTS

3rd Floor, Satyam Building,
Opp. Old Vuda Office, Fatehgunj,
Vadodara - 390 002, Gujarat, India
M.: +91 8758756360
Website : www.maheshudhwani.com

Independent Auditor's Review Report on the Unaudited Standalone Financial Results of KRONOX LAB SCIENCES LIMITED for quarter and half year ended September 30, 2026 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review report to
The Board of Directors
KRONOX LAB SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of **KRONOX LAB SCIENCES LIMITED** for the quarter ended 30th September 2026 and half year ended 30th September 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

The Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus

MAHESH UDHWANI & ASSOCIATES
VADODARA
CHARTERED ACCOUNTANTS

provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

We draw attention to Note 4 to the accompanying Statement, indicating that Pursuant to Share Purchase Agreement executed between the erstwhile Promoters of the Company and Indo Borax & Chemicals Limited on August 20,2026, the Equity Shares of the Company representing 64.26% of the Paid-up Equity Shares Capital were transferred to Indo Borax & Chemicals Limited on September 29, 2026. Consequently, Indo Borax Chemicals Limited became the Holding Company. Pursuant to change in controlling stake in the Company, there is a change in the Board of Directors and Key Managerial Personnel of the Company effective from September 29, 2026.

Our conclusion is not modified in respect of this matter.

For Mahesh Udhwani & Associates
Chartered Accountants
FRN :129738W

MAHESH UDHWANI & ASSOCIATES BARODA CHARTERED ACCOUNTANTS

Mahesh Udhwani
Partner
M.N: 047328
UDIN: 26047328BJNBPK8513
Place: Vadodara
Date: 05/11/2026